Changes
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]
{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|align = "center" bgcolor = "#4F81BD" colspan = "2"|'''Sanofi-Aventis Animal Health'''
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Financial Details'''
|-
|'''Total Company Revenue in 2010'''
|align = "center"|$ 30.384 Bn
|-
|'''Revenue from Animal Health Market in 2010'''
|align = "center"|$ 2.635 Bn
|-
|'''% of revenue from Animal Health in 2010'''
|align = "center"|8.67%
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Segmentwise Revenue Breakup ($ Bn)'''
|-
|'''Livestock Vaccines'''
|align = "center"|1.021
|-
|'''Companion Vaccines'''
|align = "center"|1.614
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Number of Major Vaccines (Animal-wise)'''
|-
|'''Poultry'''
|align = "center"|0
|-
|'''Swine'''
|align = "center"|0
|-
|'''Fish'''
|align = "center"|0
|-
|'''Sheep'''
|align = "center"|0
|-
|'''Cattle'''
|align = "center"|0
|-
|'''Canine'''
|align = "center"|3
|-
|'''Feline'''
|align = "center"|2
|-
|'''Equine'''
|align = "center"|2
|-
|bgcolor = "#95B3D7"|'''Mergers and Acquisitions (2009 - 2011)'''
|align = "center" bgcolor = "#95B3D7"|'''Consideration'''
|-
|'''Merial Ltd'''
|align = "center"|$ 4 Bn
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Future Focus Areas'''
|-
|'''Veterinary Vaccines under trial'''
|align = "center"|0
|-
|rowspan = "2"|'''Future Focus Areas of the company in the Veterinary Vaccines Market'''
|Viral and parasitological vaccines
|-
|In pharmaceutical R&D, we have 120 ongoing projects focusing on parasiticides, anti-infectives and internal medicine (endocrine/pain) and performance products. Meanwhile in biological R&D, we have 140 projects in progress focusing on zoonotic and emerging diseases, respiratory diseases, enteric diseases and enabling technologies.
|-
|}
<br> <br>
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]
{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|align = "center" bgcolor = "#4F81BD" colspan = "2"|'''Sanofi-Aventis Animal Health'''
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Financial Details'''
|-
|'''Total Company Revenue in 2010'''
|align = "center"|$ 30.384 Bn
|-
|'''Revenue from Animal Health Market in 2010'''
|align = "center"|$ 2.635 Bn
|-
|'''% of revenue from Animal Health in 2010'''
|align = "center"|8.67%
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Segmentwise Revenue Breakup ($ Bn)'''
|-
|'''Livestock Vaccines'''
|align = "center"|1.021
|-
|'''Companion Vaccines'''
|align = "center"|1.614
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Number of Major Vaccines (Animal-wise)'''
|-
|'''Poultry'''
|align = "center"|0
|-
|'''Swine'''
|align = "center"|0
|-
|'''Fish'''
|align = "center"|0
|-
|'''Sheep'''
|align = "center"|0
|-
|'''Cattle'''
|align = "center"|0
|-
|'''Canine'''
|align = "center"|3
|-
|'''Feline'''
|align = "center"|2
|-
|'''Equine'''
|align = "center"|2
|-
|bgcolor = "#95B3D7"|'''Mergers and Acquisitions (2009 - 2011)'''
|align = "center" bgcolor = "#95B3D7"|'''Consideration'''
|-
|'''Merial Ltd'''
|align = "center"|$ 4 Bn
|-
|align = "center" bgcolor = "#95B3D7" colspan = "2"|'''Future Focus Areas'''
|-
|'''Veterinary Vaccines under trial'''
|align = "center"|0
|-
|rowspan = "2"|'''Future Focus Areas of the company in the Veterinary Vaccines Market'''
|Viral and parasitological vaccines
|-
|In pharmaceutical R&D, we have 120 ongoing projects focusing on parasiticides, anti-infectives and internal medicine (endocrine/pain) and performance products. Meanwhile in biological R&D, we have 140 projects in progress focusing on zoonotic and emerging diseases, respiratory diseases, enteric diseases and enabling technologies.
|-
|}
<br> <br>
Go back to [http://dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report#Company_Snapshot homepage]
